Skip to main content

Advertisement

Table 3 Effect of type of anaesthesia on the efficacy and safety of dabigatran etexilate: event rates observed with the different types of anaesthesia for each therapy

From: Type of anaesthesia and the safety and efficacy of thromboprophylaxis with enoxaparin or dabigatran etexilate in major orthopaedic surgery: pooled analysis of three randomized controlled trials

Outcome General anaesthesia Neuraxial anaesthesia Combination
Dabigatran etexilate 220 mg
 Major VTE and VTE-related mortality 4.0% (23/578) 2.7% (29/1080) 2.7% (10/369)
  OR (95% CI) versus general anaesthesia   0.67 (0.37–1.22) 0.67 (0.28–1.49)
 MBE 0.9% (7/785) 1.7% (24/1379) 1.4% (7/497)
  OR (95% CI) versus general anaesthesia   1.97 (0.82–5.43) 1.59 (0.47–5.34)
 MBE/CRBE 4.8% (38/785) 5.9% (81/1379) 6.0% (30/497)
  OR (95% CI) versus general anaesthesia   1.23 (0.82–1.87) 1.26 (0.74–2.12)
Dabigatran etexilate 150 mg
 Major VTE and VTE-related mortality 5.1% (30/587) 3.2% (35/1082) 3.3% (13/395)
  OR (95% CI) versus general anaesthesia   0.62 (0.37–1.06) 0.63 (0.30–1.27)
 MBE 1.3% (10/781) 1.0% (14/1403) 0.8% (4/530)
  OR (95% CI) versus general anaesthesia   0.78 (0.32–1.97) 0.59 (0.13–2.05)
 MBE/CRBE 5.4% (42/781) 5.4% (76/1403) 6.6% (35/530)
  OR (95% CI) versus general anaesthesia   1.01 (0.67–1.52) 1.24 (0.76–2.03)
Enoxaparin
 Major VTE and VTE-related mortality 3.5% (20/566) 3.2% (37/1143) 3.1% (12/383)
  OR (95% CI) versus general anaesthesia   0.91 (0.51–1.68) 0.88 (0.39–1.92)
 MBE 1.3% (10/745) 1.5% (21/1430) 1.6% (8/512)
  OR (95% CI) versus general anaesthesia   1.10 (0.49–2.62) 1.17 (0.40–3.31)
 MBE/CRBE 4.6% (34/745) 5.6% (80/1430) 4.5% (23/512)
  OR (95% CI) versus general anaesthesia   1.24 (0.81–1.93) 0.98 (0.55–1.74)
  1. No statistically significant differences were observed between the dabigatran etexilate treatment groups and enoxaparin.
  2. VTE, venous thromboembolism; OR, odds ratio; CI, confidence interval; MBE, major bleeding event; CRBE, clinically relevant bleeding event.